KORU MEDICAL SYSTEMS INC (KRMD)
Health Care · Subcutaneous drug delivery and infusion systems · NASDAQ
Koru Medical manufactures FREEDOM Infusion Systems for at-home subcutaneous drug delivery, primarily for immunoglobulin therapy in immunodeficiency diseases, while generating services revenue from pharma partnerships in novel subcutaneous drug development.
What KORU MEDICAL SYSTEMS INC does
Koru Medical develops and manufactures large-volume subcutaneous infusion systems, primarily the FREEDOM Infusion Systems (including syringe drivers, tubing, and needle sets), for drug delivery governed by FDA regulations and international quality standards. The company generates revenue from three streams: domestic and international core product sales of infusion devices for subcutaneous drugs (primarily immunoglobulin treatment for Primary Immunodeficiency Diseases and CIDP), and pharma services including clinical trial feasibility studies and non-recurring engineering services for biopharmaceutical companies developing novel subcutaneous therapies.
Themes: ["subcutaneous immunoglobulin (SCIg) delivery"]
Fundamentals
- Price$4.43 as of 2026-07-09 close
- Market cap$203M as of 2026-07-10
- 1-year return+16.6% as of 2026-07-09 close
- Net margin-5.3% as of 2026-07-10
- Gross margin+61.9% as of 2026-07-10
- ROE-13.6% as of 2026-07-10
- Debt / equity0.01 as of 2026-07-10
- Revenue growth (YoY)+23.3% as of 2026-07-10
- Revenue CAGR (3y)+13.8% SEC XBRL
- Beta0.44 as of 2026-07-10
Key risks (from latest filing)
["Company is unprofitable with a net margin of -5.27% and accumulated deficit of $32.8 million as of Q1 2026; sustained operating losses could impair liquidity and equity."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.